Pre-specified secondary analysis of CONVINCE (3,100 patients with non-cardioembolic stroke or TIA): colchicine's effect on recurrent MACE did not vary by stroke subtype (P=0.64 for interaction), e.g. large-artery 12.3% vs 16% (HR 0.77).
Secondary analysisn = 3,100
Maes et al. Effect of colchicine for secondary prevention according to stroke subtype: A secondary analysis of the CONVINCE randomized trial